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Abstract
Purpose: Optimal screening for ocular toxicity caused by
chloroquine and hydroxychloroquine is still controver-
sial. With the multifocal pattern electroretinogram
(mfPERG), a new electrophysiological technique has re-
cently become available to detect early changes of gan-
glion cells. In this study this new technique is applied to a
series of 10 patients seen consecutively receiving long-
term chloroquine medication. Methods: In 10 patients
receiving chloroquine medication, clinical examination,
Amsler visual field testing and computerized color vision
testing were performed. If toxicity was suspected, auto-
mated perimetry was carried out. In addition, in all
patients conventional pattern electroretinogram (PERG)
and mfPERG testing were performed. Results: On clinical
examination 8 patients showed no chloroquine-associ-
ated maculopathy, while 2 patients did. Of these 2, only
1 reported abnormalities when viewing the Amsler chart,
while automated perimetry showed typical, ring-like
paracentral scotomas in both affected patients and color
vision was significantly abnormal. In the normal pa-
tients, 4 of 8 had a mild color vision disturbance, which
correlated to age-related macular changes. The ampli-
tudes of the PERG and the central (approximately 10°)
responses of the mfPERG were markedly reduced in
chloroquine maculopathy, while the latencies were un-
changed. The peripheral rings of mfPERG (ranging to
48°) were not affected by chloroquine toxicity. Both
PERG and mfPERG were less affected by age-related
macular changes. Conclusions: The reduction of PERG
and central mfPERG responses in chloroquine maculo-
pathy may help with the early detection of toxicity.
Copyright © 2004 S. Karger AG, Basel
Introduction
Screening strategies for antimalarial retinal toxicity are
still controversial, because there is a difficulty in defining
the early stages of retinopathy, and in well-monitored
patients, the incidence of retinopathy is low. Macular
changes and transient defects in visual field testing as well
as in color vision testing may be symptoms of a ‘prereti-
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nopathy’, but are difficult to differentiate from other
causes such as age-related changes. While all screening
strategies include visual acuity testing and a dilated fun-
dus exam, and many include fundus photographs, other
tests like fluorescein angiography [1] or more frequently
visual field tests ranging from Amsler grid [2] to auto-
mated macular perimetry [3–5] have been used. Also, var-
ious color vision tests have been proposed [6] and differ-
ent electrophysiological tests (electro-oculogram and elec-
troretinogram, ERG) have been evaluated [7–14]. The
efficiency of all such ophthalmologic screening proce-
dures is controversial. This is reflected in surveys of cur-
rent practice patterns showing quite inhomogeneous re-
sults [15]. Recently, proposed screening requirements are
more and more limited to clinical tests [5, 16] and for
hydroxychloroquine no routine ophthalmologic screening
is recommended by the Royal College of Ophthalmolo-
gists [17]. The recent recommendations of the American
Academy of Ophthalmology [5, 16] adopt screening inter-
vals after a baseline exam for both antimalarials because
of the anticipated risk to the patient. The proposed rou-
tine screening includes an ophthalmologic exam and
visual field testing by an Amsler grid or Humphrey 10-2.
Optional tests include color testing, fundus photography,
fluorescein angiography and multifocal ERG.
While early studies and some recent literature [5, 16]
assumed that a binding of chloroquine to melanin caused
retinal toxicity [18, 19], there is strong proof that melanin
is not at all concerned in ocular toxicity [20]. This is sup-
ported by the fact that retinopathy can be reproduced
equally both in albino and in pigmented rabbits, rats and
cats [21–25]. Several histopathologic investigations report
retinal changes, which showed membranous cytoplasmic
bodies predominantly in the ganglion cells of the retina in
man [26], monkey [27] and rodents [28], whereas the pig-
ment epithelium was affected only in very advanced reti-
nopathy. This mechanism of first impairing ganglion cell
function proposes that the strategy for chloroquine reti-
nopathy screening must focus on those cells. Of the elec-
trophysiological tests, therefore, theoretically the pattern
ERG (PERG) should be the most effective [29], but has
been applied in only a few cases [30]. As retinopathy is
known to occur predominantly in the macula, multifocal
techniques are very promising [5]. Therefore, the aim of
the current study was to investigate if screening for ocular
toxicity of antimalarials can be improved by using the
PERG and multifocal PERG.
Methods
Patients
A series of 10 consecutive patients presenting at the electrophysi-
ological department of the ophthalmologic department at the Ludwig
Maximilians University were included in the study.
On every exam besides full clinical examination, Amsler visual
field testing and color vision testing with a computerized color vision
test as described below [31–33], applying 6.5° orthotypes, were per-
formed. If chloroquine retinopathy was suspected, automated perim-
etry (Humphrey 30-2 and/or 10-2; Carl Zeiss Inc., Dublin, Calif.,
USA) was also performed. The patient characteristics are given in
table 1.
As a control group we examined 25 age-matched normal eyes
from 25 healthy individuals. Informed consent was obtained from all
participants. Average mean and standard deviation (SD) of the
healthy subject ages was 61 B 12 (range 21–72) years. Healthy eyes
had no eye disease on ophthalmologic examination and no history of
any chronic eye disease or previous ocular surgery. Visual acuity for
normal volunteers was 1.0 (20/20) or better with correction.
PERG and Multifocal PERG Stimulation
For the PERG a RETIScan System (Roland Consult, Wiesbaden,
Germany) was used. The conventional, transient PERG was per-
formed according to the ISCEV Standards [34] applying a 1°25)
checkerboard and 200 averages. For each PERG a positive compo-
nent at approximately 50 ms (P-50) and a negative component at
approximately 95 ms (N-95) was determined. The total amplitude
P-50–N-95 was analyzed. Normal values were determined to have a
median of 13.7 ÌV with a 95% interval of 6.7–22.7 ÌV yielding a
lower limit of 6.7 ÌV.
For the multifocal, transient PERG also a RETIScan System
(Roland Consult) was applied, presenting a stimulus pattern of 19
patterned hexagons, each consisting of 6 triangles (which are alter-
nating black and white). No scaling factor was applied, which means
that the central hexagon (macula) had the same size (9.6° visual
field) as the peripheral hexagons. The stimulus was presented on a
21-inch monitor viewed at 30 cm distance within a central 48 °
visual field (visual angle of 24°). Mean luminance of the stimulus on
the monitor was 180 cd/cm² and the contrast was approximately
98%. Each hexagon changed at the frequency of 75 Hz with an on/off
probability of 0.5. A trace array of all multifocal PERG traces was
smoothed and plotted.
Recording and Response Analysis
For all recordings gold foil electrodes were used (reference elec-
trodes at the temple, ground electrodes at the forehead) after anesthe-
tizing the conjunctiva with oxybuprocain 0.4% eye drops. Near cor-
rection if necessary was applied. For fixation a red target of approxi-
mately 1° visual angle was placed in the center of the stimulus. The
room illumination was moderate and always the same [35], and no
mydriatic eye drops were given.
The pattern changed in accordance of the structure of a corrected
m-sequence [36]. Duration of data acquisition was approximately
5 min with a length of 512 divided into 10 sessions of 39 s each. The
signals were band-pass-filtered with a high cut at 300 Hz and a low
cut at 10 Hz. In case of artifacts due to ocular movement or eyelid
movement, the response was eliminated by the computer program.
By cross-correlation analysis between stimulation patterns and their
responses 19 focal multifocal PERGs were displayed topographi-
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Table 1. Patient data with results of computer color vision testing, conventional PERG, multifocal PERG (mfPERG) and clinical assess-
ment
Patient No.
and eye
Age Visual
acuity
Duration of
chloroquine
medication
Daily dose
mg/kg ideal
body weight
Color test
threshold, %
protan tritan
PERG
amplitude
P-50–N-95
ÌV
mfPERG amplitude
P-50–N-95 nV/deg2
ring 1 ring 2 ring 3
Clinical assessment
1 OD 62 0.8 4 years 5 17.8 38.2 1.9 7.2 7.0 3.6 chloroquine maculopathy
1 OS 1.0 18.4 39.0 4.8 4.3 6.0 3.7 chloroquine maculopathy
2 OD 64 0.3 20 years 10 40.0 70.0 4.0 2.6 2.9 2.1 chloroquine maculopathy
2 OS 0.5 21.0 22.0 6.0 6.7 2.5 2.7 chloroquine maculopathy
3 OD 62 0.9 6 years 4 2.9 8.1 15.0 8.9 9.1 4.5 dry ARM
3 OS 0.9 2.3 9.9 21.0 14.4 6.5 4.8 dry ARM
4 OD 30 1.25 1 year 2.8 5.2 6.0 7.7 12.6 7.6 3.4 normal
4 OS 1.25 5.0 3.7 7.8 20.4 7.4 6.7 normal
5 OD 42 1.0 3 years 2.5 6.4 7.0 21.0 36.6 13.6 6.2 normal
5 OS 1.0 6.4 6.2 23.0 31.8 12.6 6.7 normal 
6 OD 25 1.0 4 years 3.0 4.8 5.2 13.0 20.5 7.3 4.9 normal
6 OS 1.0 5.0 4.8 18.0 19.9 11.5 6.0 normal
7 OD 66 0.8 5 years 8 7.2 8.6 8.8 17.8 5.6 2.4 dry ARM
7 OS 0.6 7.8 9.1 8.3 22.4 2.8 4.9 dry ARM
8 OD 76 1.0 1 year 2.5 9.4 10.4 9.2 11.2 4.2 2.0 dry ARM
8 OS 1.0 8.4 9.8 12.0 8.9 6.0 3.5 dry ARM
9 OD 67 1.0 6 months 3.0 4.8 7.2 13.0 21.7 9.9 5.1 normal
9 OS 0.8 7.2 9.4 10.0 13.1 8.9 3.0 normal, corneal scar
10 OD 43 1.0 20 years 3.5 4.8 6.2 6.0 4.3 3.3 0.6 retinal scars, ARM
10 OS 1.0 4.6 6.4 7.5 13.0 5.0 2.6 retinal scars, ARM
Normal values for color testing were less than 8% threshold, for PERG amplitudes more than 6.7 ÌV. Multifocal PERG normal reference
intervals start from 21.7 nV/deg2 for the central ring, from 8.1 nV/deg2 for ring 2 and from 4.1 nV/deg2 for ring 3. ARM = Early forms of
age-related maculopathy.
cally. For analysis the 19 hexagons were grouped into one central
field and two peripheral rings.
For each multifocal PERG a positive component at approximate-
ly 50 ms (P-50) and a negative component at approximately 95 ms
(N-95) were determined. The P-50 often rises from a still earlier neg-
ative wave at approximately 35 ms (N-35). The positive component
is measured from this trough to the following positive peak of P-50.
The following negative N-95 component is measured from the peak
of P-50 to the following trough at approximately 95 ms. The total
amplitude P-50–N-95 was used for analysis and responses were
grouped into three regions: a central hexagon (macular hexagon), a
middle ring (6 hexagons) and a peripheral ring (remaining 12 hexa-
gons). The responses of the peripheral rings were averaged from the
underlying hexagons. Latencies (given in milliseconds) of N-35, P-50
and N-95 were also measured and analyzed for every ring. As they
did not show any alterations, data are not shown.
Color Vision Test
A computerized color vision test was used. The details of the
method are described in detail elsewhere [31–33]. In brief, the system
uses a calibrated 21-inch color monitor to present random letters as
targets to be identified. The letters are of equal luminance to the
background and can only be recognized because their hue differs
from the background. Color of the letters is varied along a chosen
confusion-confusion axis. A modified binary search is carried out to
determine the threshold color contrast along protan and tritan color
confusion lines. The resulting threshold should not exceed 8.0% in
normal probands and is known to be almost independent of age when
applying large 6.5° orthotypes as performed in this study [33].
Thresholds of 8.0% for protan and tritan axis were used according to
Berninger et al. [33], where 7.0% was found as an extreme value for
protan axis and 7.9% for tritan axis in normals. The threshold repre-
sents a deviation of more than 3 SD for protan and 2 SD for tritan
from the normal mean.
Statistics
All data were collected and analyzed using SPSS 11.0 for Win-
dows (SPSS Inc., Chicago, Ill., USA). In all cases nonparametrical
tests were used and always only the right eye of each patient (and
controls) included.
Results
The patient details are given in table 1. Mean patient
age was 54 B 17 years (range 25–76 years) and did not
differ from normal controls. In table 1 all results of test-
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ing: color vision, PERG, and multifocal PERG, are listed.
The results were analyzed for significant differences in col-
or vision thresholds, the amplitudes of the PERG, differ-
ences in amplitudes from negative N-95 to positive P-50 in
multifocal PERG and for differences in the latencies.
Color Vision Testing
Regarding color vision, patients with chloroquine
maculopathy showed a marked increase in thresholds for
protan (p = 0.06) and tritan color axis (p = 0.06; Mann-
Whitney U test) within the shown patient group. All toxic
maculopathies were by far exceeding the normal thresh-
olds of 8%. Eyes with a maculopathy due to early age-
related changes (ARM) showed also some abnormal color
test results as compared to the normal control group. For
the protan axis only 1 patient with ARM (patient 8 in
table 1) exceeded the threshold of normals, while most
patients with ARM showed slightly abnormal values for
the tritan axis.
PERG Testing
In the 2 patients with chloroquine maculopathy, the
amplitudes of conventional PERG testing (table 1) were
outside the lower reference limit for healthy individuals of
6.7 ÌV. In contrast, nearly all other patients including
those with early ARM did exceed this minimal amplitude.
Even when comparing within all 8 patients on chlo-
roquine to those 2 with chloroquine maculopathy (ta-
ble 1), a significant reduction in PERG amplitudes at p =
0.04 was obtained.
Multifocal PERG Testing
On multifocal PERG testing the multifocal PERG P-
50–N-95 amplitudes of the normal age-matched control
group were 37.37 B 7.83 nV/deg2 for the central ring,
15.82 B 3.87 nV/deg2 for ring 2 and 9.50 B 2.69 nV/deg2
for ring 3 (each representing mean B SD). This calculated
2 SD lower reference limits of 21.7 nV/deg2 for the central
ring, 8.1 nV/deg2 for ring 2 and 4.1 nV/deg2 for ring 3. For
all cases with established maculopathy a clear reduction
throughout all rings was observed with the central ring
showing the by far largest reduction of amplitudes (ta-
ble 1). The patients with ARM also exhibited some degree
of central reduction as did other pathologies such as cor-
neal or central retinal scars. However, those changes were
less pronounced than in chloroquine maculopathy.
Throughout all patients with any maculopathy the periph-
eral ring 3 was affected least.
When comparing the multifocal PERG amplitudes
within all patients taking chloroquine (all patients from
table 1), the 2 maculopathy cases exhibited the largest dif-
ference for the central ring (p = 0.07), less pronounced in
ring 2 (p = 0.19), while for the peripheral ring 3 no differ-
ence was found (p = 0.60). When those 4 patients with
ARM changes were excluded from analysis, similar re-
sults were obtained. When comparing within table 1 only
those eyes with age-related changes to those 2 with chloro-
quine-induced maculopathy, overall the largest statistical
differences were obtained for color vision testing (p =
0.06), the conventional PERG (p = 0.06) and ring 1 of
multifocal PERG (p = 0.17). One case example with
established maculopathy will be described here briefly to
illustrate the typical changes.
Case Example
The 62-year-old woman (table 1, patient 1) was first
seen 2 years ago with a developing bilateral bull’s-eye
maculopathy, the right eye more than the left eye (fig. 1a).
She had suffered from rheumatoid arthritis for 24 years
and taken a 250-mg chloroquine tablet daily for the last 4
years (cumulative dose 365 g). The recommended daily
dose for this patient, based on her ideal body weight for
her height (158 cm), would be only 175 mg/day, so the
actual dosage was high. The patient’s general ophthalmol-
ogist was following her with automated 30° visual fields,
where in both eyes central absolute scotomas developed
within the last 6 months before presentation to our
department (fig. 1b). These visual field changes had oc-
curred at first without any and later on with subtle fundus
changes (fig. 1a) alarming him of retinopathy. Best-cor-
rected visual acuity at first presentation was on the right
0.8 (20/25) and on the left 1.0 (20/20). The patient showed
a marked cornea verticillata and on funduscopy early
bull’s-eye maculopathy (fig. 1a). The patient herself had
recognized a slightly blurred vision for some months, but
could not localize any defect on Amsler grid testing. Con-
ventional multifocal ERG was completely normal, indi-
cating no photoreceptor dysfunction. However, the
PERG (fig. 1c, table 1) and central multifocal PERG am-
plitudes (fig. 1d, table 1) were markedly reduced. The col-
or vision test was highly pathologic. It yielded for protan
axis OD 17.8% and OS 18.4% (normal !8%), and for tri-
tan axis OD 38.2% and OS 39.0% (normal !8%). The
patient discontinued chloroquine and has had stable vi-
sual acuity for 2 years now with constantly improving col-
or vision and PERGs.
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Fig. 1. a Fundus picture of the left eye of patient 1 with chloroquine
maculopathy. Visual acuity was 1.0. The other eye showed similar
changes. b Central 10° visual field (Humphrey 10-2) of the left eye of
the same patient shows a typical paracentral scotoma. The defects
correlate well with the fundus picture in a. c Conventional PERG
shows markedly reduced amplitudes with a mean P-50–N-95 of
4.8 ÌV. The scale is 20 ms/Div and 5 ÌV/Div. d Multifocal PERG by
monitor stimulation on a RETIScan System (Roland Consult) shows
reduced central responses. In addition the curve form in the central
hexagon changed in a way so that N-95 could hardly be determined.
Each hexagon corresponds to 9.6° of visual field. The markers in the
traces represent N-35 and P-50. e The multifocal PERG trace of a
60-year-old normal patient is plotted for comparison.
Discussion
Toxicity
While early studies assumed a binding of chloroquine
to melanin to cause retinal toxicity [18, 19], it is nowadays
known that melanin is not the primary mechanism of
ocular toxicity [20–25]. Histopathologic investigations
showed membranous cytoplasmic bodies predominantly
in the ganglion cells of the retina in both man [26], mon-
key [27] and rodents [28], whereas the pigment epithe-
lium showed only changes in very advanced retinopathy.
In this study it is shown on a small group of patients
receiving long-term chloroquine medication that both
full-field PERG and central multifocal PERG responses
are reduced in retinal chloroquine toxicity. Additionally,
the tritan color axis is earlier affected than the protan sys-
tem [37], which may support the theory that ganglion cells
in the macula are the primary site of chloroquine toxicity,
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which mainly generate the PERG responses [34]. How-
ever, other more distal effects such as luminance-depen-
dent influences from photoreceptors or even pigment epi-
thelium damage may still contribute to the decrease of the
PERG responses. While the changes more altering the
response at N-95 than at P-50 (fig. 1d) hint towards a gan-
glion cell affection, the other causes mentioned cannot be
completely excluded from this limited patient series.
Regarding the underlying mechanism, lipid complex
accumulation causes ganglion cells to develop complex-
containing lysosomes, Müller and bipolar cells being first
affected [22]. As far as is known, chloroquine forms com-
plexes with gangliosides, inhibiting further degradation
[38] and finally leading to an accumulation of lipid com-
plexes in the neuroretina [39, 40]. Ultimately this may
cause irreversible damage to rods and cones even after
cessation of the drug [41, 42]. This explains why the mul-
tifocal ERG is suitable for detecting more advanced chlo-
roquine retinopathy [43, 44]. However, changes in rods
and cones occur in more advanced toxicity, thus limiting
all tests on this system [37].
Color Vision
Defects in color vision are known to occur with anti-
malarial treatment that causes retinal toxic changes [45]
and may precede visible fundus changes [46]. However,
changes may be subtle and frequently are not detected by
conventional color testing [47–52]. It is known that the
earliest changes resulting from retinal toxicity occur with
blue-yellow (i.e. tritan) colors, while protan defects occur
in more advanced cases [53, 54]. This explains why every
color test is not equally applicable. We have previously
shown that the computerized, quantitative color test used
in this study has a high sensitivity and specificity for
chloroquine-induced maculopathy [37]. Additionally, it
has the advantage that it can be performed fast and easily
(less than 5 min for both eyes). When using large opto-
types, there is only a trivial disturbance in color percep-
tion due to age [33].
Visual Field Testing
Visual field testing is frequently performed for moni-
toring [15] since it was first proposed by Hart et al. [3] in
1984. Definite maculopathy is defined by Easterbrook
[52, 55] as reproducible bilateral field defects, while early
maculopathy does not show visual field defects [56]. The
use of Amsler grid for testing is inexpensive and fast and
therefore is frequently recommended [2, 5, 15, 16, 57].
However, it is very dependent on the compliance of the
patient and nonspecific as approximately 6% of the nor-
mal population has defects [50]. Amsler grid testing may
still give hints and allow a less frequent use of automated
static perimetry [16].
Although routinely many centers use static 10-2 auto-
mated perimetry, only few reports exist regarding its suit-
ability for screening. Easterbrook [58] found 91% sensi-
tivity and 58% specificity for a red perimetry, which is in
the range of color vision tests. Interestingly, in our case
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series, early visual field changes (see case report) showed
an arcuate scotoma similar to that seen in glaucoma. This
further supports the theory that ganglion cells are first
affected, as it is known that maximal ganglion cell densi-
ties are reached in a horizontally oriented, elliptical ring
0.4–2.0 mm from the foveal center [59]. This is also the
area where first changes are seen in chloroquine retinopa-
thy, leaving the foveal center unchanged (fig. 1), although
in the foveal center the highest melanin contents of the
overall low melanized macula are found [60, 61]. In more
advanced, later forms only the typical ring-like scotoma is
found at the area of highest ganglion cell density corre-
sponding to secondary changes of the retinal pigment epi-
thelium. As changes of ganglion cells can be well mea-
sured by the PERG [62], it is reasonable to apply this test
to detect early chloroquine retinopathy, representing a
‘ganglion cellopathy’ in early stages. In this study we could
show in a first case series that in chloroquine retinopathy
usually both full-field PERG and central multifocal
PERG responses are reduced, but no changes are found in
patients without retinal toxicity.
Conclusions
The reduction of PERG and central multifocal PERG
responses in chloroquine maculopathy may help with the
early detection of toxicity.
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